|Bid||170.11 x 800|
|Ask||170.26 x 800|
|Day's Range||170.00 - 172.72|
|52 Week Range||146.80 - 179.84|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||60.06|
|Forward Dividend & Yield||1.88 (1.10%)|
|1y Target Est||N/A|
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
CVS Health's (CVS) year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services.
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4.
PRA Health (PRAH) posts year-over-year double-digit growth in earnings, revenues and net new business in Q3. However, increasing labor-related costs in the Clinical Research wing are a concern.
Hill-Rom (HRC) benefits from a robust year-over-year revenue increase on solid domestic growth in Q4, driven by a strong segmental performance at both Patient Support Systems and Front Line Care.
Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.